Epstein-Barr virus gene expression in post-transplant lymphoproliferative disorders

Springer Seminars in Immunopathology

Volumn 20, Issue 3-4, 1998, Pages 389-403

  Rowe, Martin ^a   Niedobitek, Gerald ^b   Young, Lawrence S ^c  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA;

CELLULAR IMMUNITY; EPSTEIN BARR VIRUS; GENE EXPRESSION; HUMAN; LATENT VIRUS INFECTION; LYMPHOPROLIFERATIVE DISEASE; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SEQUENCE ANALYSIS; T LYMPHOCYTE; TRANSPLANTATION; VIRUS GENE;

EID: 0031771204     PISSN: 03444325     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00838051     Document Type: Review

References (73)

1. Adldinger HK, Delius H, Freese UK, Clarke J, Bornkamm GW (1985) A putative transforming gene of Jijoye virus differs from that of Epstein-Barr virus prototypes. Virology 141:221
2. +T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing. Immunity 7:791
3. Borisch B, Gatter KC, Tobler A, Theilkäs L, Bunch C, Wainscoat JS, Fey MF (1992) Epstein-Barr virus-associated anaplastic large cell lymphoma in renal transplant patients. Am J Clin Pathol 98:312
4. Chen ML, Tsai CN, Liang CL, Shu CH, Huang CR, Sulitzeanu D, Liu ST, Chang YS (1992) Cloning and characterization of the latent membrane protein (LMP) of a specific Epstein-Barr virus variant derived from the nasopharyngeal carcinoma in the Taiwanese population. Oncogene 7:2131
5. Dambaugh T, Hennessy K, Chamnankit L, Kieff E (1984) U2 region of Epstein-Barr virus DNA may encode Epstein-Barr nuclear antigen 2. Proc Natl Acad Sci USA 81:7632
6. Delecluse HJ, Kremmer E, Rouault JP, Cour C, Bornkamm GW, Berger F (1995) The expression of Epstein-Barr virus latent proteins is related to pathological features of post-transplant lymphoproliferative disorders. Am J Pathol 146:1113
7. Delecluse HJ, Rouault JP, Ffrench M, Dureau G, Magaud JP, Berger F (1995) Post-transplant lymphoproliferative disorders with genetic abnormalities commonly found in malignant tumours. Br J Haematol 89:90
8. Finke J, Rowe M, Kallin B, Ernberg I, Rosén A, Dillner J, Klein G (1987) Monoclonal and polyclonal antibodies against Epstein-Barr virus nuclear antigen 5 (EBNA-5) detect multiple protein species in Burkitt's lymphoma and lymphoblastoid cell lines. J Virol 61:3870
9. Frank D, Cesarman E, Liu YF, Michler RE, Knowles DM (1995) Posttransplantation lymphoproliferative disorders frequently contain type A and not type B Epstein-Barr virus. Blood 85:1396
10. Garnier J-L, Lebranchu Y, Dantal J, Bedrossian J, Cahen R, Assouline D, Jaccard A, Fetissoff F, Moreau A, Martin X, Delsol G, Berger F, Touraine J-L (1996) Hodgkin's disease after transplantation. Transplantation 61:71
11. Gavioli R, De Campos-Lima PO, Kurilla MG, Kieff E, Klein G, Masucci MG (1992) Recognition of the Epstein-Barr virus-encoded nuclear antigens EBNA-4 and EBNA-6 by HLA-A11-restricted cytotoxic T lymphocytes: implications for down-regulation of HLA-A11 in Burkitt lymphoma. Proc Natl Acad Sci USA 89:5862
12. Gratama JW, Ernberg I (1995) Molecular epidemiology of Epstein-Barr virus infection. Adv Cancer Res 67:197
13. Gratama JW, Zutter MM, Minarovits J, Oosterveer MAP, Thomas ED, Klein G, Ernberg I (1991) Expression of Epstein-Barr virus-encoded growth-transformation-associated proteins in lymphoproliferations of bone-marrow transplant recipients. Int J Cancer 47:188
14. Gregory CD, Rowe M, Rickinson AB (1990) Different Epstein-Barr virus (EBV)-B cell interactions in phenotypically distinct clones of a Burkitt lymphoma cell line. J Gen Virol 71:1481
15. Hamilton-Dutoit SJ, Rea D, Raphael M, Sandvej K, Delecluse HJ, Gisselbrecht C, Marelle L, Krieken JHJMvan, Pallesen G (1993) Epstein-Barr virus-latent gene expression and tumor cell phenotype in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Correlation of lymphoma phenotype with three distinct patterns of viral latency. Am J Pathol 143:1072
16. Hanto DW, Frizzera G, Gajl-Peczalska KJ, Sakamoto K, Purtilo DT, Balfour HH, Simmons RL, Najarian JS (1982) Epstein-Barr virus-induced B-cell lymphoma after renal transplantation. Acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation. N Engl J Med 306:913
17. Haque T, Thomas JA, Falk KI, Parratt R, Hunt BJ, Yacoub M, Crawford DH (1996) Transmission of donor Epstein-Barr virus (EBV) in transplanted organs causes lymphoproliferative disease in EBV-seronegative recipients. J Gen Virol 77:1169
18. Hu L-F, Chen F, Zheng X, Ernberg I, Cao S-L, Christensson B, Klein G, Winberg G (1993) Clonability and tumorigenicity of human epithelial cells expressing the EBV encoded membrane protein LMP1. Oncogene 8:1575
19. Huen DS, Henderson SH, Croom-Carter D, Rowe M (1995) The Epstein-Barr virus latent membrane protein (LMP1) mediates activation of NF-κB and cell surface phenotype via two effector regions in its carboxyl-terminal cytoplasmic domain. Oncogene 10:549
20. Johnson R, Stack M, Hazlewood SA, Blackmore C, Hu L-F, Rowe M (1998) The 30 bp deletion in Chinese variants of the Epstein-Barr virus LMP1 gene is not the major effector of functional differences between LMP1 variants in human lymphocytes. J Virol 72:4038
21. Khanim F, Yao QY, Niedobitek G, Sihota S, Rickinson AB, Young LS (1996) Analysis of Epstein-Barr virus gene polymorphisms in normal donors and in virus-associated tumors from different geographic locations. Blood 88:3491
22. Khanna R, Burrows SR, Kurilla MG, Jacob CA, Misko IS, Sculley TB, Kieff E, Moss DJ (1992) Localization of Epstein-Barr virus cytotoxic T-cell epitopes using recombinant vaccinia - implications for vaccine development. J Exp Med 176:169
23. Khanna R, Burrows SR, Nicholls J, Poulsen LM (1998) Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype-restricted immune-recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes. Eur J Immunol 28:451
24. Kieff E (1996) Epstein-Barr virus and its replication. In: Fields BN, Knipe DM, Howley PM (eds) Fields virology, vol 2, 3rd edn. Lippincott-Raven, Philadelphia, pp 2343-2396
25. Kingma DW, Weiss WB, Jaffe ES, Kumar S, Frekko K, Raffeid M (1996) Epstein-Barr virus latent membrane protein-1 oncogene deletions: correlations with malignancy in Epstein-Barr virus-associated lymphoproliferative disorders and malignant lymphomas. Blood 88:242
26. Knowles DM, Cesarman E, Chadbum A, Frizzera G, Chen J, Rose EA, Michler RE (1995) Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 85:552
27. Kremmer E, Kranz BR, Hille A, Klein K, Eulitz M, Hoffmannfezer G, Feiden W, Herrmann K, Delecluse HJ, Delsol G, Bornkamm GW (1995) Rat monoclonal antibodies differentiating between the Epstein-Barr virus nuclear antigens 2A (EBNA2A) and 2B (EBNA2B). Virology 208:336
28. Kumar S, Kumar D, Kingma DW, Jaffe ES (1993) Epstein-Barr virus-associated T-cell lymphoma in a renal transplant patient. Am J Surg Pathol 17:1046
29. Lee SP, Thomas WA, Murray RJ, Khanim F, Kaur S, Young LS, Rowe M, Kurilla M, Rickinson AB (1993) HLA A2.1-restricted cytotoxic T-cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2. J Virol 67:7428
30. Levitskaya J, Coram M, Levitsky V, Imreh S, Steigerwald-Mullen PM, Klein G, Kurilla M, Masucci MG (1995) The internal repeat region of the Epstein-Barr virus nuclear antigen-1 is a cis-acting inhibitor of antigen processing. Nature 375:685
31. Li S-N, Chang Y-S, Liu S-H (1996) Effect of a 10-amino acid deletion on the oncogenic activity of latent membrane 1 of Epstein-Barr virus. Oncogene 12:2129
32. Masucci MG, Torsteinsdottir S, Colombani J, Brautbar C, Klein E, Klein G (1987) Down-regulation of class-1 HLA antigens and of the Epstein-Barr virus (EBV)-encoded latent membrane protein (LMP) in Burkitt's lymphoma lines. Proc Natl Acad Sci USA 84:4567
33. Maunders MJ, Petti L, Rowe M (1994) Precipitation of the Epstein-Barr virus protein EBNA 2 by an EBNA 3c-specific monoclonal antibody. J Gen Virol 75:769
34. Miller WE, Edwards RH, Walling DM, Raab-Traub N (1994) Sequence variation in Epstein-Barr virus latent membrane protein-1. J Gen Virol 75:2729
35. Montone KT, Hodinka RL, Salhany KE, Lavi E, Rostami A, Tomaszewski JE (1996) Identification of Epstein-Barr virus lytic activity in post-transplantation lymphoproliferative disease. Mod Pathol 9:621
36. Murray RJ, Kurilla MG, Brooks JM, Thomas WA, Rowe M, Kieff E, Rickinson AB (1992) Identification of target antigens for the human cytotoxic T-cell response to Epstein-Barr virus (EBV) - implications for the immune control of EBV-positive malignancies. J Exp Med 176:157
37. Niedobitek G, Agathanggelou A, Rowe M, Jones EL, Jones DB, Turyaguma P, Oryema J, Wright DH, Young LS (1995) Heterogeneous expression of Epstein-Barr virus latent proteins in endemic Burkitt's lymphoma. Blood 86:659
38. Niedobitek G, Agathanggelou A, Herbst H, Whitehead L, Wright DH, Young LS (1997) Epstein-Barr virus (EBV) infection in infectious mononucleosis: virus latency, replication and phenotype of EBV-infected cells. J Pathol 182:151
39. Niedobitek G, Mutimer DJ, Williams A, Whitehead L, Wilson P, Rooney N, Young LS, Hubscher SG (1997) Epstein-Barr virus infection and malignant lymphomas in liver transplant recipients. Int J Cancer 73:514
40. Nonkwelo C, Henson EBD, Sample J (1995) Characterisation of the Epstein-Barr virus Fp promoter. Virology 206:183
41. Ometto L, Menin C, Masiero S, Bonaldi L, Del Mistro A, Cattelan AM, D'Andrea E, De Rossi A, Chieco-Bianchi L (1997) Molecular profile of Epstein-Barr virus in human immunodeficiency virus type 1-related lymphadenopathies and lymphomas. Blood 90:313
42. O'Reilly RJ, Small TN, Papadopoulos E, Lucas K, Lacerda J, Koulova L (1997) Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts. Immunol Rev 157:195
43. Oudejans JJ, Jiwa M, Brule AJC van den, Grässer FA, Horstman A, Vos W, Kluin PM, Valk P van der, Meijer CJLM (1995) Detection of heterogeneous Epstein-Barr virus gene expression patterns within individual post-transplant lymphoproliferative disorders. Am J Pathol 147:923
44. Patton DF, Wilkowski CW, Hanson CA, Shapiro R, Gajl-Peczalska KJ, Filipovich AH, McClain KL (1990) Epstein-Barr virus-determined clonality in posttransplant lymphoproliferative disease. Transplantation 49:1080
45. Rea D, Delecluse HJ, Hamilton-Dutoit SJ, Marelle L, Joab I, Edelman L, Finet JF, Raphael M (1994) Epstein-Barr virus latent and replicative gene expression in post-transplant lymphoproliferative disorders and AIDS-related non-Hodgkin's lymphomas. French Study Group of pathology for HIV-associated tumors. Ann Oncology 5 [Suppl] 1:113
46. Rea D, Fourcade C, Leblond V, Rowe M, Joab I, Edelman L, Bitker M-O, Gandjbakhch I, Suberbielle C, Farcet J-P, Raphael M (1994) Patterns of EBV latent and replicative gene expression in EBV B-cell lymphoproliferative disorders after organ transplantation. Transplantation 58:317
47. Rickinson AB, Kieff E (1996) Epstein-Barr virus. In: Fields BN, Knipe DM, Howley PM (eds) Fields virology, vol 2. Lippincott-Raven, Philadelphia, pp 2397-2446
48. Rickinson AB, Young LS, Rowe M (1987) Influence of the Epstein-Barr virus nuclear antigen EBNA 2 on the growth phenotype of virus-transformed B cells. J Virol 61:1310
49. Rooney CM, Smith CA, Heslop HE (1997) Control of virus-induced lymphoproliferation: Epstein-Barr virus-induced lymphoproliferation and host immunity. Mol Med Today 3:24
50. Rowe DT, Rowe M, Evan GI, Wallace LE, Farrell PJ, Rickinson AB (1986) Restricted expression of EBV latent genes and T-lymphocyte-detected membrane antigen in Burkitt's lymphoma cells. EMBO J 5:2599
51. Rowe M, Rowe DT, Gregory CD, Young LS, Farrell PJ, Rupani H, Rickinson AB (1987) Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma. EMBO J 6:2743
52. Rowe M, Young LS, Cadwallader K, Petti L, Kieff E, Rickinson AB (1989) Distinction between Epstein-Barr virus type A (EBNA 2A) and type B (EBNA 2B) isolates extends to the EBNA 3 family of nuclear proteins. J Virol 63:1031
53. Rowe M, Young LS, Crocker J, Stokes H, Henderson S, Rickinson AB (1991) Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man. J Exp Med 173:147
54. Rowe M, Lear A, Croom-Carter D, Davies AH, Rickinson AB (1992) Three pathways of Epstein-Barr virus (EBV) gene activation from EBNA1-positive latency in B lymphocytes. J Virol 66:122
55. Rowe M, Khanna R, Jacob CA, Argaet V, Kelly A, Powis S, Belich M, Croom-Carter D, Lee S, Burrows S, Trowsdale J, Moss DJ, Rickinson AB (1995) Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA class I antigen expression. Eur J Immunol 25:1374
56. Sample J, Young L, Martin B, Chatman T, Kieff E, Rickinson A, Kieff E (1990) Epstein-Barr virus type-1 (EBV-1) and 2 (EBV-2) differ in their EBNA 3A, EBNA 3B, and EBNA3C genes. J Virol 64:4084
57. Sandvej K, Munch M, Hamilton-Dutoit SJ (1996) Mutations in the Epstein-Barr virus latent membrane protein-1 (BNLF-1) gene in spontaneous lymphoblastoid cell lines: effect on in vitro transformation associated parameters and tumorigenicity in SCID and nude mice. J Clin Pathol 49:M290
58. Schaefer BC, Strominger JL, Speck SH (1995) Redefining the Epstein-Barr virus-encoded nuclear antigen EBNA-1 gene promoter and transcription initiation site in group I Burkitt lymphoma cell lines. Proc Natl Acad Sci USA 92:10565
59. Scheinfeld AG, Nador RG, Cesarman E, Chadburn A, Knowles DM (1997) Epstein-Barr virus latent membrane protein-1 oncogene deletion in post-transplantation lymphoproliferative disorders. Am J Pathol 151:805
60. Sung NS, Edwards RH, Seillier-Moiseiwitsch F, Perkins AG, Zeng Y, Raab-Traub N (1998) Epstein-Barr virus strain variation in nasopharyngeal carcinoma from the endemic and non-endemic regions of China. Int J Cancer 76:207
61. Tao Q, Robertson KD, Manns A, Hildesheim A, Ambinder RF (1998) Epstein-Barr virus (EBV) in endemic Burkitt's lymphoma: molecular analysis of primary tumor tissue. Blood 91:1373
62. Thomas JA, Hotchin NA, Allday MJ, Amlot P, Rose M, Yacoub M, Crawford DH (1990) Immunohistology of Epstein-Barr virus-associated antigens in B cell disorders from immunocompromised individuals. Transplantation 49:944
63. Waller EK, Ziemianska M, Bangs CD, Cleary M, Weissman I, Kamel OW (1993) Characterization of posttransplant lymphomas that express T-cell-associated markers: immunophenotypes, molecular genetics, cytogenetics, and heterotransplantation in severe combined immunodeficiency mice. Blood 82:247
64. Wang F, Gregory CD, Sample C, Rowe M, Liebowitz D, Murray R, Rickinson AB, Kieff E (1990) Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J Virol 64:2309
65. Wang F, Tsang S-F, Kurilla MG, Cohen JI, Kieff E (1990) Epstein-Barr virus nuclear antigen 2 transactivates latent membrane protein LMP1. J Virol 64:3407
66. Wu T-T, Swerdlow SH, Locker J, Bahler D, Randhawa P, Yunis EJ, Dickman PS, Nalesnik MA (1996) Recurrent Epstein-Barr virus-associated lesions in organ transplant recipients. Hum Pathol 27:157
67. Yao QY, Rowe M, Martin B, Young LS, Rickinson AB (1991) The Epstein-Barr virus carrier state: dominance of a single growth-transforming isolate in the blood and in the oropharynx of healthy virus carriers. J Gen Virol 72:1579
68. Yao QY, Croom-Carter DSG, Tierney RJ, Habeshaw G, Wilde JT, Hill FGH, Conlon C, Rickinson AB (1998) Epidemiology of infection with Epstein-Barr virus types 1 and 2: lessons from the study of a T-cell-immunocompromised hemophilic cohort. J Virol 72:4352
69. Young L, Alfieri C, Hennessey K, Evans H, O'Hara C, Anderson KC, Ritz J, Shapiro RS, Rickinson A, Kieff E, Cohen JI (1989) Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med 321:1080
70. Young LS, Yao QY, Rooney CM, Sculley TB, Moss DJ, Rupani H, Laux G, Bornkamm GW, Rickinson AB (1987) New type B isolates of Epstein-Barr virus from Burkitt's lymphoma and from normal individuals in Burkitt-endemic areas. J Gen Virol 68:2853
71. Young LS, Lau R, Rowe M, Niedobitek G, Packham G, Shanaham F, Rowe DT, Greenspan D, Greenspan JS, Rickinson AB, Farrell PJ (1991) Differentiation-associated expression of the Epstein-Barr virus BZLF1 transactivator protein in oral "hairy" leukoplakia. J Virol 65:2868
72. Zimber U, Adldinger HK, Lenior GM, Vuillaume M, Von Knebel-Doeberitz M, Laux G, Desgranges C, Wittman P, Freese UK, Schneider U, Bornkamm GW (1986) Geographical prevalence of two Epstein-Barr virus types. Virology 154:56
73. Zimber-Strobl U, Suentzenich KO, Laux G, Eick D, Cordier M, Calender A, Billaud M, Lenoir GM, Bomkamm GW (1991) Epstein-Barr virus nuclear antigen 2 activates transcription of the terminal protein gene. J Virol 65:415